NRIX NASDAQ
Nurix Therapeutics, Inc.
1W: -0.1%
1M: -11.0%
3M: -4.4%
YTD: +27.3%
1Y: +144.6%
3Y: +176.3%
5Y: -30.0%
$22.99
-0.35 (-1.50%)
Weekly Expected Move ±5.2%
$21
$22
$23
$24
$25
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
2 bullish
0 neutral
0 bearish
Articles (7d)
2
Daily Sentiment (7 Days)
Articles (100)
Precigen (PGEN) Soars 6.3%: Is Further Upside Left in the Stock?
Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer
842,089 Shares in Nurix Therapeutics, Inc. $NRIX Bought by Bank of America Corp DE
AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates
Here's Why You Should Add NRIX Stock to Your Portfolio Now
Nurix Therapeutics (NRIX) Upgraded to Buy: Here's Why
Jupiter Topco LLC Invests $594,000 in Nurix Therapeutics, Inc. $NRIX
Bank of New York Mellon Corp Purchases New Shares in Nurix Therapeutics, Inc. $NRIX
Can KT-621 Mark a Turning Point for Kymera Therapeutics?
California State Teachers Retirement System Has $1.53 Million Holdings in Nurix Therapeutics, Inc. $NRIX
Nurix Therapeutics (NASDAQ:NRIX) Reaches New 1-Year High After Analyst Upgrade
Dimensional Fund Advisors LP Purchases 349,710 Shares of Nurix Therapeutics, Inc. $NRIX
Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Is Kymera Therapeutics Poised for a Breakthrough With KT-621?
Roche H1 Sales Decline on Currency Headwinds, Key Drugs Keep Momentum
Amova Asset Management Americas Inc. Sells 109,408 Shares of Nurix Therapeutics, Inc. $NRIX
RHHBY's Gazyva Gets FDA Priority Review for Label Expansion
Company News for July 13, 2026
Nurix Therapeutics, Inc. (NRIX) Reports Q2 Loss, Lags Revenue Estimates
Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Roche Reports Positive Results From Head-to-Head Study on NSCLC Drug
Earnings Preview: Nurix Therapeutics, Inc. (NRIX) Q2 Earnings Expected to Decline
Wall Street Analysts Believe Nurix Therapeutics (NRIX) Could Rally 29.23%: Here's is How to Trade
Roche Gets FDA Priority Review for Enspryng in Thyroid Eye Disease
Nurix Therapeutics, Inc. (NRIX) Price Target Raised to $33 on Roche Partnership Value
Nurix Stock Up 29% in a Month: Here's What You Should Know
Nurix Therapeutics (NRIX) Soars 16.4%: Is Further Upside Left in the Stock?
$NRIX stock is up 16% today. Here's what we see in our data. - Quiver Quantitative
Flax Pond Capital LLC Invests $1.52 Million in Nurix Therapeutics, Inc. $NRIX - MarketBeat
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Roche–Nurix Bexobrutideg Alliance Might Change The Case For Investing In Nurix Therapeutics (NRIX) - simplywall.st
Nurix Therapeutics (NRIX) Stock Looks Expensive Even With A $31 Analyst Target
Truist is Bullish on Nurix Therapeutics, Inc. (NRIX)
Truist is Bullish on Nurix Therapeutics, Inc. (NRIX)
Truist is Bullish on Nurix Therapeutics, Inc. (NRIX) - Yahoo Finance
Nurix Therapeutics (NRIX) Stock Looks Expensive Even With A $31 Analyst Target - Yahoo Finance
Canopy Growth Corporation (CGC) Reports Q4 Loss, Lags Revenue Estimates
Canopy Growth Corporation (CGC) Reports Q4 Loss, Lags Revenue Estimates
Kymera, Monte Rosa among gainers as Novartis inks deal for molecular glue drugs
Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy
Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy
TG Therapeutics (TGTX) Soars 7.5%: Is Further Upside Left in the Stock?
TG Therapeutics (TGTX) Soars 7.5%: Is Further Upside Left in the Stock?
Strength Seen in Nurix Therapeutics (NRIX): Can Its 6.8% Jump Turn into More Strength?
Company News for Jun 9, 2026
Company News for Jun 9, 2026
Nurix Therapeutics: 'Strong Buy' Due To Roche Deal And Bexobrutideg Expansions - Seeking Alpha
Strength Seen in Nurix Therapeutics (NRIX): Can Its 6.8% Jump Turn into More Strength? - Yahoo Finance
Company News for Jun 9, 2026 - Yahoo Finance
Broader Market Settles Higher as Chipmakers Rally
Roche Inks $2.3 Billion Deal, Sending This Small Biotech Stock Flying
Roche's $2.3 Billion Nurix Deal Sends Shares Moving
Roche Licenses Nurix Therapeutics Blood-Cancer Drug for Up to $2.3 Billion
Roche, Nurix Team Up to Advance BTK Degrader Bexobrutideg
Stocks Rally as Buyers Return After AI-Led Selloff
This Biotech Stock Is Popping 10% on $2.3 Billion Roche Deal for Blood Cancer Drug
Stocks Push Higher as Chipmakers and AI Companies Rebound
Roche stakes $700M on Nurix’s protein-degrading drug
Nurix Therapeutics Gains Ground As Roche Partnership Targets Growing B-Cell Blood Cancer Market
Roche and Nurix strike $2.3 billion blood cancer drug deal
12 Health Care Stocks Moving In Monday's Pre-Market Session
Roche signs $2.3bn blood cancer drug agreement with Nurix Therapeutics
NRIX Stock Surges Nearly 70% Premarket Today – Roche And Nurix’s Blood Cancer Drug Collaboration Can Tap A $41B Market
Why Marvell Technology Shares Are Trading Higher By 7%; Here Are 20 Stocks Moving Premarket
Nurix surges 43% on up to $3B cancer drug deal with Roche
NRIX Stock Chops Lower As Insider Form 4 Hits Tape - StocksToTrade
Nurix jumps as investors digest newly announced global Roche partnership for BTK degrader bexobrutideg - Quiver Quantitative
Roche Inks $2.3 Billion Deal, Sending This Small Biotech Stock Flying - Investor's Business Daily
Biggest stock movers Monday: NRIX, INTC, and more (NASDAQ:NRIX) - Seeking Alpha
Jefferies Financial Group Issues Positive Forecast for Nurix Therapeutics (NASDAQ:NRIX) Stock Price - MarketBeat
Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology
Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology
Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology
Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurology
NRIX Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Stock Declines - Financial Data - lwvtexas.org
Insider Sale: Chief Legal Officer of $NRIX Sells 8,148 Shares | NRIX Stock News - Quiver Quantitative
Nurix Therapeutics Presents New Preclinical and Phase 1 Translational Data Supporting Bexobrutideg (NX-5948) in Chronic Spontaneous Urticaria at the 2026 Society for Investigative Dermatology Annual Meeting
Is Nurix Therapeutics (NRIX) Stock’s Premium P/S Multiple Fair After Recent Mixed Share Price Performance - Yahoo Finance
A Nurix Therapeutics (NRIX) Insider Sold 5,394 Shares for $90,000
Nurix Therapeutics Announces New Preclinical Data Highlighting Breadth of Targeted Protein Degradation Pipeline at AACR 2026
Did Sanofi Revenue Expiry and Rising R&D Spend Just Recast Nurix Therapeutics' (NRIX) Investment Narrative? - Yahoo Finance
Does Nurix Therapeutics (NRIX) Have the Potential to Rally 85.84% as Wall Street Analysts Expect?
Does Nurix Therapeutics (NRIX) Have the Potential to Rally 85.84% as Wall Street Analysts Expect? - Yahoo Finance
Company News for Apr 9, 2026
Earnings Scheduled For April 8, 2026
Nurix Therapeutics, Inc. (NRIX) Reports Q1 Loss, Lags Revenue Estimates
Nurix Therapeutics GAAP EPS of -$0.79 misses by $0.02, revenue of $6.25M misses by $7.99M
Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
Nurix Therapeutics to Participate in Upcoming Investor Conference
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Receives Consensus Rating of “Moderate Buy” from Analysts
A Look At Nurix Therapeutics (NRIX) Valuation After Strong 1 Year Return And High Price To Sales Ratio - Yahoo Finance
Alpha Cognition Inc. (ACOG) Reports Q4 Loss, Lags Revenue Estimates
Nurix Therapeutics (NRIX) Moves 6.9% Higher: Will This Strength Last?
Precigen, Inc. (PGEN) Reports Q4 Loss, Lags Revenue Estimates
12 Health Care Stocks Moving In Wednesday's After-Market Session
Nurix Therapeutics Announces Multiple Presentations Showcasing Depth of Research Pipeline and Scientific Leadership at the American Association for Cancer Research (AACR) 2026 Annual Meeting
Sol-Gel Technologies Ltd. (SLGL) Reports Q4 Loss, Misses Revenue Estimates
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Receives Average Rating of “Moderate Buy” from Analysts
Nurix Therapeutics, Inc. $NRIX Stock Position Increased by Amova Asset Management Americas Inc.